HD-OPM Archive
Topics › Brain health & dementia

CETP inhibitors might help prevent Alzheimer's and Lewy body dementia in APOE4 carriers

Louis Nervegna · May 24, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
Brain health & dementiaPCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

Louis shares a breakdown of why a lipid drug class could affect the brain: APOE is the brain's main cholesterol carrier, and a 2024 Mendelian randomization found the CETP benefit strongest in APOE4 carriers. It cites genetic and biomarker evidence, but this is early and not proof of clinical benefit.

More on why cholesterol drugs, specifically CETP inhibitors, might prevent or treat Alzheimer’s and Lewy Body Dementia (LBD), especially in ApoE4’s.

(Note that ApoE4 raises the risk for Lewy Body Dementia, as well as Alzheimer’s.)

Quoted:

Why would a cholesterol drug touch the brain? Because APOE is the main cholesterol-carrier protein in your brain. Block CETP, raise HDL particles AND the ApoE riding on them, and synthetic HDL clears amyloid from brain vessels (mouse data). And genetics predicted it: Mendelian randomization in 2024 showed the CETP benefit was MOST PRONOUNCED in APOE4+ carriers. LBD odds ratio 0.61 in APOE4+ vs 0.89 in non-carriers, interaction p = 5.81 x 10^-4. 2006 Barzilai centenarians: CETP VV variant doubled odds of MMSE > 25. 2015 Cache County: CETP I405V slowed cognitive decline by 0.6 points/year per valine. Note: Cache County did NOT link CETP I405V to Alzheimer's diagnosis — trajectory not disease prevention. Convergence across 20 years of genetics, MR, and now a Phase 3 biomarker readout.

Full breakdown at the link in bio.

#cetpinhibitorHD #apoe4HD #alzheimersHD #dementiaHD #hdlHD #obicetrapibHD #lewybodydementiaHD

Research cited

← newer: FDA keeps icosapent ethyl (Vascepa) approved for CV risk redolder: High protein does not harm kidneys in healthy people, but ma →